Compare StocksABBV vs AKAM

AbbVie Inc. (ABBV) vs Akamai Technologies, Inc. (AKAM): Which Is the Better Buy in 2026?

As of 2026-06-19, ABBV is overvalued at $216, with a DCF intrinsic value of $160 and a margin of safety of -35%. AKAM is overvalued at $125, with an intrinsic value of $28 and a margin of safety of -353%. Of the two, ABBV has the wider margin of safety.

ABBV
AbbVie Inc.
$216.49
VS
AKAM
Akamai Technologies, Inc.
$124.91

Rewards

ABBV
  • AbbVie Inc. has maintained ROIC above 10% for 4 consecutive years, suggesting solid business economics.
  • Gross margin of 72.0% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • AbbVie Inc. scores 82/100 on the Economic Moat Score (Wide Moat), with reinvestment efficiency as the strongest competitive dimension.
AKAM

    Risks

    ABBV
    • Buybacks have been poorly timed — 3 out of 4 years involved repurchases at relatively expensive valuations.
    • FCF yield of 5.4% suggests reasonable valuation assuming continued moderate growth.
    • Trailing P/E of 105.6x is 69% above the historical average of 62.3x — the stock trades at a premium to its own history.
    AKAM
    • Trailing P/E of 42.2x is 46% above the historical average of 28.8x — the stock trades at a premium to its own history.
    • Net debt/EBITDA of 4.3x indicates heavy leverage — it would take over 4 years of EBITDA to pay off net debt.
    • Free cash flow has declined at a 5.0% CAGR over the past 4 years — a concerning trend.

    Key Valuation Metrics

    Learn more →
    ABBV
    AKAM
    Valuation
    $20.81B
    Free Cash Flow
    $700.72M
    5.44%
    FCF Yield
    3.86%
    105.60
    Trailing P/E
    42.20
    13.32
    Forward P/E
    17.49
    Quality & Moat
    21.89%
    ROIC
    3.32%
    N/A
    ROE
    9.17%
    72.03%
    Gross Margin
    58.28%
    0.61
    PEG Ratio
    1.57
    Balance Sheet Safety
    N/A
    Net Debt / Equity
    1.01
    N/A
    Interest Coverage
    N/A
    2.12
    Net Debt / EBITDA
    4.30
    3.11%
    Dividend Yield
    0.00%
    ABBV: 8Ties: 1AKAM: 1
    ABBVAKAM

    Historical Fundamentals

    Learn more →
    ABBV

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    AKAM

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    $1 Retained Earnings Test

    Learn more →
    ABBV
    N/A
    Net losses over 3 years — test not applicable
    Company had negative cumulative retained earnings
    Σ Retained
    $-19.85B
    Δ Market Cap
    +$118.02B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
    AKAM
    $-0.38
    created per $1 retained over 3 years
    Market Cap Declined
    Σ Retained
    $1.50B
    Δ Market Cap
    $-566.5M
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Discounted Cash Flow (DCF) Analysis

    Learn more →
    ABBV
    35.3% Overvalued
    Price is 35.3% above estimated fair value
    Current Price: $216.49
    Fair Value: $160.05
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued
    AKAM
    353.4% Overvalued
    Price is 353.4% above estimated fair value
    Current Price: $124.91
    Fair Value: $27.55
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued

    Reverse DCF — Market-Implied Growth

    Learn more →
    ABBV

    What growth rate is the market pricing in at $216?

    +17.1%
    Market-Implied Owner Earnings Growth
    Standard FCF implies +8.7%

    The market implies +17.1% Owner Earnings growth, above historical trends.

    Standard FCF implies a demanding +8.7%, reflecting heavy growth investment.

    AKAM

    What growth rate is the market pricing in at $125?

    +20.5%
    Market-Implied Owner Earnings Growth
    Standard FCF implies +14.5%

    The market implies +20.5% Owner Earnings growth, above historical trends.

    Standard FCF implies a demanding +14.5%, reflecting heavy growth investment.

    Economic Moat Score

    Learn more →
    ABBV
    82/100
    Wide Moat
    70+ Wide · 40-69 Narrow · <40 None

    Wide moat with strength across all dimensions. Reinvestment Efficiency is the standout factor.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.
    AKAM
    53/100
    Narrow Moat
    70+ Wide · 40-69 Narrow · <40 None

    Narrow moat with revenue predictability as the key competitive advantage. Improving roic consistency would strengthen the moat.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.

    Forensic Accounting

    Learn more →
    ABBV
    -2.86
    Unlikely Manipulator
    Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

    M-Score Trend

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
    AKAM
    -2.80
    Unlikely Manipulator
    Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

    M-Score Trend

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Ownership Breakdown

    Learn more →
    ABBV
    Insiders 0.1%Institutions 76.9%Retail & Other 23.0%
    No. of Institutional Holders5,106
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
    AKAM
    Insiders 2.1%Institutions 111.6%
    No. of Institutional Holders1,096
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

    High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

    Insider Buying Activity

    Learn more →
    ABBV
    0
    Buys (3M)
    0
    Buys (12M)
    No open market insider purchases found.
    Open market purchases · includes direct & indirect ownership · excludes option exercises
    AKAM
    0
    Buys (3M)
    2
    Buys (12M)
    Total value (12M): $3.83M
    HESSE DANIEL R
    Director
    $216,897
    @ $72.30 · 2025-08-11
    LEIGHTON F THOMSON
    Chief Executive Officer
    $3.61M
    @ $72.26 · 2025-08-11
    LEIGHTON F THOMSON
    Chief Executive Officer
    $3.00M
    @ $79.58 · 2025-02-27
    Open market purchases · includes direct & indirect ownership · excludes option exercises

    Open market purchases · includes direct & indirect ownership · excludes option exercises.

    Insider Selling Activity

    Learn more →
    ABBV
    0
    Sells (3M)
    5
    Sells (12M)
    Total value (12M): $21.79M
    PURDUE DAVID R.
    Officer
    $1.22M
    @ $233.56 · 2026-03-04
    SIATIS PERRY C.
    General Counsel
    $4.38M
    @ $234.39 · 2026-03-02
    SIATIS PERRY C.
    General Counsel
    $5.15M
    @ $230.00 · 2026-02-25
    SALEKI-GERHARDT AZITA
    Chief Operating Officer
    $8.41M
    @ $198.42 · 2025-08-12
    DONOGHOE NICHOLAS
    Officer
    $2.64M
    @ $198.51 · 2025-08-05
    STEWART JEFFREY RYAN
    Officer
    $12.36M
    @ $210.08 · 2025-03-31
    REENTS SCOTT T.
    Chief Financial Officer
    $3.75M
    @ $212.34 · 2025-03-14
    GONZALEZ RICHARD A
    Director
    $20.26M
    @ $205.45 · 2025-03-03
    SIATIS PERRY C.
    General Counsel
    $5.82M
    @ $208.69 · 2025-03-03
    RICHMOND TIMOTHY J
    Officer
    $4.47M
    @ $210.45 · 2025-03-03
    BUCKBEE KEVIN K
    Officer
    $3.85M
    @ $203.41 · 2025-02-26
    RICHMOND TIMOTHY J
    Officer
    $6.07M
    @ $202.90 · 2025-02-26
    SIATIS PERRY C.
    General Counsel
    $1.14M
    @ $197.90 · 2025-02-20
    BUCKBEE KEVIN K
    Officer
    $310,032
    @ $172.24 · 2024-12-16
    GONZALEZ RICHARD A
    Officer and Director
    $12.40M
    @ $186.52 · 2024-08-05
    GONZALEZ RICHARD A
    Officer and Director
    $49.50M
    @ $175.00 · 2024-07-17
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
    AKAM
    1
    Sells (3M)
    20
    Sells (12M)
    Total value (12M): $12.70M
    SALEM-JACKSON KIM
    Officer
    $311,811
    @ $135.57 · 2026-06-10
    JOSEPH PAUL C
    Officer
    $531,256
    @ $106.25 · 2026-03-16
    KARON ADAM M
    Officer
    $1.83M
    @ $107.43 · 2026-03-12
    WILLIAMS ANTHONY P
    Officer
    $1.56M
    @ $104.29 · 2026-03-11
    MCGOWAN EDWARD J
    Chief Financial Officer
    $1.39M
    @ $101.19 · 2026-03-10
    RANGANATHAN MADHU
    Director
    $319,362
    @ $102.00 · 2026-03-04
    MILLER JONATHAN FRANK
    Director
    $1.13M
    @ $102.67 · 2026-03-04
    KARON ADAM M
    Officer
    $458,190
    @ $96.91 · 2026-03-02
    HOWELL LAURA
    Officer
    $1.13M
    @ $100.14 · 2026-02-25
    BLUMOFE ROBERT
    Chief Technology Officer
    $378,000
    @ $108.00 · 2026-02-13
    BLUMOFE ROBERT
    Chief Technology Officer
    $339,500
    @ $97.00 · 2026-01-22
    JOSEPH PAUL C
    Officer
    $450,874
    @ $90.17 · 2026-01-15
    KARON ADAM M
    Officer
    $289,836
    @ $87.30 · 2026-01-02
    MCGOWAN EDWARD J
    Chief Financial Officer
    $577,477
    @ $88.03 · 2025-12-15
    JOSEPH PAUL C
    Officer
    $438,451
    @ $87.69 · 2025-11-17
    BLUMOFE ROBERT
    Chief Technology Officer
    $263,051
    @ $87.68 · 2025-11-14
    BLUMOFE ROBERT
    Chief Technology Officer
    $301,000
    @ $86.00 · 2025-11-07
    JOSEPH PAUL C
    Officer
    $383,250
    @ $76.65 · 2025-09-15
    BLUMOFE ROBERT
    Chief Technology Officer
    $231,000
    @ $77.00 · 2025-08-22
    JOSEPH PAUL C
    Officer
    $388,700
    @ $77.74 · 2025-07-15
    BLUMOFE ROBERT
    Chief Technology Officer
    $253,714
    @ $77.97 · 2025-06-12
    SALEM-JACKSON KIM
    Officer
    $1.00M
    @ $76.33 · 2025-05-27
    KARON ADAM M
    Officer
    $333,863
    @ $85.02 · 2025-05-08
    JOSEPH PAUL C
    Officer
    $333,480
    @ $83.37 · 2025-03-18
    WILLIAMS ANTHONY P
    Officer
    $780,805
    @ $82.19 · 2025-03-17
    KARON ADAM M
    Officer
    $811,943
    @ $82.34 · 2025-03-11
    MCGOWAN EDWARD J
    Chief Financial Officer
    $971,911
    @ $82.34 · 2025-03-11
    KARON ADAM M
    Chief Operating Officer
    $485,140
    @ $86.20 · 2025-03-10
    MCGOWAN EDWARD J
    Chief Financial Officer
    $402,305
    @ $86.48 · 2025-03-10
    KARON ADAM M
    Chief Operating Officer
    $517,632
    @ $80.49 · 2025-03-04
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

    🎭 Mr. Market's Mood

    Learn more →
    ABBV
    FearGreed
    😐Neutral(56/100)

    "Market is pricing this stock without strong emotion in either direction"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
    AKAM
    FearGreed
    😨Fear(33/100)

    "Market is pessimistic — investigate whether fears are temporary or structural"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    ⚖️ Buffett Signal

    Learn more →
    ABBV
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Neutral (56)
    AKAM
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Fear (33)
    View ABBV Full AnalysisView AKAM Full Analysis

    Frequently Asked Questions: ABBV vs AKAM

    Is AbbVie Inc. or Akamai Technologies, Inc. more undervalued in 2026?

    Based on our discounted cash flow model, ABBV trades at a -35.3% margin of safety (intrinsic value $160 vs. price $216), compared to AKAM's -353.4% margin of safety (intrinsic $28 vs. $125).

    Which stock has a wider economic moat, AbbVie Inc. or Akamai Technologies, Inc.?

    ABBV scores 82/100 (Wide moat), while AKAM scores 53/100 (Narrow moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

    Is Akamai Technologies, Inc. in financial distress?

    AKAM's Altman Z-Score of 2.3 places it in the Grey zone, signaling elevated bankruptcy risk. ABBV scores 2.4 (Grey zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

    Which company has better free cash flow, AbbVie Inc. or Akamai Technologies, Inc.?

    AbbVie Inc. (ABBV) generates a 5.4% free cash flow yield, compared to Akamai Technologies, Inc.'s 3.9%. A higher FCF yield means the business converts more of its market value into cash that can be returned to shareholders or reinvested.

    Which stock has higher return on invested capital, AbbVie Inc. or Akamai Technologies, Inc.?

    ABBV earns 21.9% ROIC versus AKAM's 3.3%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.